Skip to main content

Table 3 Evaluation of MSC exosomes therapeutic potential in clinical trial registered in ClinicalTrials.gov (January 2021)

From: Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities

Condition

Study phase

Participant number

Cell source

Cell type

Delivery route

Location

NCT number

ARDS

1/2

169

n.a

Allogeneic

Inhalation

China

NCT04602104

COVID-19

1

24

AT

Allogeneic

Inhalation

China

NCT04276987

MODS

n.a

60

n.a

Allogeneic

IV

China

NCT04356300

Pulmonary infection

1/2

60

AT

Allogeneic

Inhalation

China

NCT04544215

AIS

1/2

5

n.a

Allogeneic

IP

Iran

NCT03384433

Dry eye

1/2

27

UC

Allogeneic

Inhalation

China

NCT04213248

Macular holes

1

44

n.a

Allogeneic

Intravitreal

China

NCT03437759

Preeclampsia

n.a

200

UC

Allogeneic

n.a

Egypt

NCT03562715

AD

1/2

9

AT

Allogeneic

Intranasal

China

NCT04388982

  1. Note; ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, MODS multiple organ dysfunction syndromes, AIS acute ischemic stroke, AD Alzheimer's diseases, AT adipose tissue, UC umbilical cord, IV intravenous, IP intraperitoneal, n.a not available